Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (2): 136-143.doi: 10.12092/j.issn.1009-2501.2022.02.003

Previous Articles     Next Articles

Effects of Shenqi fuzheng injection on low-glucose-mediated immunosuppressive microenvironment and its mechanism of action

MA Wangbo1,2, Ma Yue1,2, FAN Fangtian1,2, ZHANG Yuhan1,2, CHANG Jingwen1,2, ZHOU Zhihua1,2   

  1. 1School of Pharmacy, Bengbu Medical College, Bengbu 233030, Anhui, China; 2Anhui Biochemical Drug Engineering Technology Research Center, Bengbu 233030, Anhui, China
  • Received:2021-11-08 Revised:2022-01-28 Online:2022-02-26 Published:2022-03-09

Abstract: AIM: To investigate the effect of Shenqi fuzheng injection (SFI) on tumor immunity and its preliminary molecular mechanism. METHODS: The animal model of low glucose tumor microenvironment was established by B16-PKM2-OE; the level of interleukin-2(IL-2) and interferon-γ(IFN-γ), CD40L and transforming growth factor-β1(TGF-β1) were detected by ELISA kit; the expressions of glucose transporter-1 (Glut-1) and key enzymes of glycolysis ( HK, PFK and PK ) in CD4+T cells were detected by Western blot. RESULTS: The results of the kit showed that SFI could increase IL-2, IFN-γ and CD40L, and decreased TGF-β1 in tumor tissues. Western blot assay showed that SFI could promote the expression of Glut-1 protein on the surface of CD4+T cell membrane, and up-regulated the expression of key enzymes of glycolysis (HK, PFK1 and PK) in a dose-dependent manner. CONCLUSION: SFI can increase the expression levels of IL-2, IFN-γ, CD40L and decrease the expression level of TGF-β1 in tumor tissues. Also, it increases the number of activated CD4+T cells in tumor tissue and promotes the glycolysis of CD4+T cells, indicating that SFI can improve the tumor immune microenvironment.

Key words: tumor infiltrating lymphocytes, Shenqi fuzheng injection, low sugar microenvironment

CLC Number: